Cancer of the ovary

New England Journal of Medicine

Volumn 330, Issue 14, 1994, Pages 1012-1014

  Lurain, John ^a   Mckay, Michael J ^b   Bull, Colin A ^b   Collazos, Julio ^c   Embil, John M ^d   Cannistra, Stephen A ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c HOSPITAL DE GALDAKAO   (Spain)

^d UNIVERSITY OF MANITOBA   (Canada)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LETTER; OVARY CANCER; PRIORITY JOURNAL; FEMALE; NOTE; OVARY TUMOR; SALVAGE THERAPY;

FEMALE; HUMAN; OVARIAN NEOPLASMS; SALVAGE THERAPY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;

EID: 0028767309     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199404073301415     Document Type: Letter

References (17)

1. Cannistra SA Cancer of the ovary. N Engl J Med 1993; 329: 1550-1559
2. Hainsworth JD, Grosh WW, Burnett LS, Jones HW III, Wolff SN, Greco FA Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165-170
3. Greco FA, Johnson DH, Hainsworth JD A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. Cancer Treat Rev 1991; 18: Suppl A: 47-55
4. Bruckner HW, Cohen C, Mandeli J, Hexamethylmelamine for the treatment of ovarian cancer — the Mount Sinai experience. Cancer Treat Rev 1991; 18: Suppl A: 57-65
5. Edmonson JH, McCormack GW, Wieand HS. Late emerging survival differences in a comparative study of HCAP vs. CP in stage III-IV ovarian carcinoma. In: Salmon SE, ed. Adjuvant therapy of cancer. 6. Proceedings of the 6th International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, March 7-10, 1990. Philadelphia: W.B. Saunders, 1990.
6. Dembo AJ Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys 1992; 22: 835-845
7. Thomas GM, Dembo AJ Integrating radiation therapy into the management of ovarian cancer. Cancer 1993; 71: Suppl: 1710-1718
8. McKay MJ, Langlands AO Prognostic factors in breast cancer. N Engl J Med 1992; 327: 1317-1317
9. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C Elevation of CA 125 in patients with benign and malignant ascites. Cancer 1987; 59: 213-217
10. Collazos J, Genolla J, Ruibal A CA 125 serum levels in patients with non-neoplastic liver diseases: a clinical and laboratory study. Scand J Clin Lab Invest 1992; 52: 201-206
11. Barrow MV Metastatic tumors of the umbilicus. J Chronic Dis 1966; 19: 1113-1117
12. Flynn VT, Spurrett BR Sister Joseph's nodule. Med J Aust 1969; 1: 728-730
13. Sapira JD. The art and science of bedside diagnosis. Baltimore: Urban and Schwarzenberg, 1990:143.
14. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-1168
15. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, Long-term survival in ovarian cancer: mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-1372
16. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group Study. J Clin Oncol 1993; 11: 440-448
17. Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RC Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 1992; 10: 727-734